Summary of clinical data from patients with severe meningococcemia and purpura fulminans who were treated with PC concentrate
| Parameter . | Results . |
|---|---|
| Mean age (range) | 12 (3 months-72 years) |
| Sex | 17 males; 18 females |
| Mechanical ventilation | 35/36 |
| Ionotropic support | 36/36 |
| PC replacement therapy | 36/36 |
| Mean time to PC therapy (range) | 12 (2-72 hours) |
| Antithrombin III replacement therapy | 2/36 |
| Unfractionated heparin | 26/36 |
| Continuous venovenous hemodiafiltration | 19/36 |
| Peritoneal dialysis | 2/36 |
| Mean GMSPS ± SD (range) | 12 ± 2 (8-15) |
| Predicted mortality | 18/36 (50%) |
| Actual mortality | 3/36 (8%) |
| Predicted amputation rate | 11/33 (30%) |
| Actual amputation rate | 4/33 (12%) |
| Amputation rate in patients who received PC within 24 hours of admission | 2/31 (6.5%) |
| Skin grafting only | 2/33 (13%) |
| Chronic renal failure requiring dialysis | 1/33 |
| Ischemic stroke | 1/33 |
| Severe meningoencephalopathy | 1/33 |
| Full recovery with no complications | 26/36 (72%) |
| Parameter . | Results . |
|---|---|
| Mean age (range) | 12 (3 months-72 years) |
| Sex | 17 males; 18 females |
| Mechanical ventilation | 35/36 |
| Ionotropic support | 36/36 |
| PC replacement therapy | 36/36 |
| Mean time to PC therapy (range) | 12 (2-72 hours) |
| Antithrombin III replacement therapy | 2/36 |
| Unfractionated heparin | 26/36 |
| Continuous venovenous hemodiafiltration | 19/36 |
| Peritoneal dialysis | 2/36 |
| Mean GMSPS ± SD (range) | 12 ± 2 (8-15) |
| Predicted mortality | 18/36 (50%) |
| Actual mortality | 3/36 (8%) |
| Predicted amputation rate | 11/33 (30%) |
| Actual amputation rate | 4/33 (12%) |
| Amputation rate in patients who received PC within 24 hours of admission | 2/31 (6.5%) |
| Skin grafting only | 2/33 (13%) |
| Chronic renal failure requiring dialysis | 1/33 |
| Ischemic stroke | 1/33 |
| Severe meningoencephalopathy | 1/33 |
| Full recovery with no complications | 26/36 (72%) |